The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InBeckman Coulter Diagnostics, a subsidiary of Danaher Corporation, has officially received the CE Mark for its Access MeMed BV assay. This innovative diagnostic tool is designed to distinguish between bacterial and viral infections in approximately 20 minutes, significantly accelerating clinical decision-making. By providing rapid results, the assay enables healthcare providers to optimize antibiotic use and reduce unnecessary hospital admissions. Economic modeling suggests that the widespread adoption of this test could save European health systems up to €80 million in avoidable costs. This regulatory milestone strengthens Danaher's position in the European medical diagnostics market and expands its high-throughput testing portfolio. Investors view this development as a positive driver for the company's long-term revenue growth in the healthcare technology sector.